Matthew R Danzig1, Katherine Mallin2, James M McKiernan3, Walter M Stadler4, Srikala S Sridhar5, Todd M Morgan6, Bernard H Bochner7, Cheryl T Lee8. 1. Division of Urology, Department of Surgery, University of Colorado, Aurora, Colorado. 2. American College of Surgeons, Commission on Cancer, Chicago, Illinois. 3. Department of Urology, Columbia University, New York, New York. 4. Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois. 5. Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, Ontario, Canada. 6. Department of Urology, University of Michigan, Ann Arbor, Michigan. 7. Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York. 8. Department of Urology, The Ohio State University, Columbus, Ohio.
Abstract
BACKGROUND: The current study was conducted to assess the impact of lymphovascular invasion on the survival of patients with urothelial carcinoma of the renal pelvis. METHODS: Patients with urothelial carcinoma of the renal pelvis who underwent radical nephroureterectomy from 2010 through 2015 were identified in the National Cancer Data Base. Patients were characterized according to demographic and clinical factors, including pathologic tumor stage and lymphovascular invasion. Associations with overall survival were assessed through proportional hazards regression analysis. RESULTS: A total of 4177 patients were identified; 1576 had lymphovascular invasion. Patients with T3 disease and lymphovascular invasion had 5-year survival that was significantly worse than that of patients with T3 disease without lymphovascular invasion (34.7% vs 52.6; P < .001 by the log-rank test), and approached that of patients with T4 disease without lymphovascular invasion (34.7% vs 26.5%; P = .002). On multivariate analysis controlling for age, comorbidities, grade, lymph node status, surgical margin status, race, sex, and chemotherapy administration, patients with T3 disease and lymphovascular invasion also were found to have significantly worse survival compared with patients with T3 disease without lymphovascular invasion (hazard ratio, 1.7; 95% confidence interval, 1.4-1.91). CONCLUSIONS: Lymphovascular invasion status is a key prognostic marker that can stratify the risk of patients with pT3 upper tract urothelial carcinoma further. Patients with this pathologic feature should be carefully considered for clinical trials exploring existing and novel therapies. Cancer 2018;124:2507-14.
BACKGROUND: The current study was conducted to assess the impact of lymphovascular invasion on the survival of patients with urothelial carcinoma of the renal pelvis. METHODS:Patients with urothelial carcinoma of the renal pelvis who underwent radical nephroureterectomy from 2010 through 2015 were identified in the National Cancer Data Base. Patients were characterized according to demographic and clinical factors, including pathologic tumor stage and lymphovascular invasion. Associations with overall survival were assessed through proportional hazards regression analysis. RESULTS: A total of 4177 patients were identified; 1576 had lymphovascular invasion. Patients with T3 disease and lymphovascular invasion had 5-year survival that was significantly worse than that of patients with T3 disease without lymphovascular invasion (34.7% vs 52.6; P < .001 by the log-rank test), and approached that of patients with T4 disease without lymphovascular invasion (34.7% vs 26.5%; P = .002). On multivariate analysis controlling for age, comorbidities, grade, lymph node status, surgical margin status, race, sex, and chemotherapy administration, patients with T3 disease and lymphovascular invasion also were found to have significantly worse survival compared with patients with T3 disease without lymphovascular invasion (hazard ratio, 1.7; 95% confidence interval, 1.4-1.91). CONCLUSIONS:Lymphovascular invasion status is a key prognostic marker that can stratify the risk of patients with pT3upper tract urothelial carcinoma further. Patients with this pathologic feature should be carefully considered for clinical trials exploring existing and novel therapies. Cancer 2018;124:2507-14.
Authors: Marco Moschini; Beat Foerster; Mohammad Abufaraj; Francesco Soria; Thomas Seisen; Morgan Roupret; Pierre Colin; Alexandre De la Taille; Benoit Peyronnet; Karim Bensalah; Roman Herout; Manfred Peter Wirth; Vladimir Novotny; Piotr Chlosta; Marco Bandini; Francesco Montorsi; Giuseppe Simone; Michele Gallucci; Giuseppe Romeo; Kazumasa Matsumoto; Pierre Karakiewicz; Alberto Briganti; Shahrokh F Shariat Journal: World J Urol Date: 2017-02-28 Impact factor: 4.226
Authors: Thomas Powles; Joseph Paul Eder; Gregg D Fine; Fadi S Braiteh; Yohann Loriot; Cristina Cruz; Joaquim Bellmunt; Howard A Burris; Daniel P Petrylak; Siew-leng Teng; Xiaodong Shen; Zachary Boyd; Priti S Hegde; Daniel S Chen; Nicholas J Vogelzang Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: Eiji Kikuchi; Vitaly Margulis; Pierre I Karakiewicz; Marco Roscigno; Shuji Mikami; Yair Lotan; Mesut Remzi; Christian Bolenz; Cord Langner; Alon Weizer; Francesco Montorsi; Karim Bensalah; Theresa M Koppie; Mario I Fernández; Jay D Raman; Wassim Kassouf; Christopher G Wood; Nazareno Suardi; Mototsugu Oya; Shahrokh F Shariat Journal: J Clin Oncol Date: 2008-12-15 Impact factor: 44.544
Authors: Nicholas J Hellenthal; Shahrokh F Shariat; Vitaly Margulis; Pierre I Karakiewicz; Marco Roscigno; Christian Bolenz; Mesut Remzi; Alon Weizer; Richard Zigeuner; Karim Bensalah; Casey K Ng; Jay D Raman; Eiji Kikuchi; Francesco Montorsi; Mototsugu Oya; Christopher G Wood; Mario Fernandez; Christopher P Evans; Theresa M Koppie Journal: J Urol Date: 2009-07-17 Impact factor: 7.450
Authors: Morgan Rouprêt; Vincent Hupertan; Thomas Seisen; Pierre Colin; Evanguelos Xylinas; David R Yates; Harun Fajkovic; Yair Lotan; Jay D Raman; Richard Zigeuner; Mesut Remzi; Christian Bolenz; Giacomo Novara; Wassim Kassouf; Adil Ouzzane; François Rozet; Olivier Cussenot; Juan I Martinez-Salamanca; Hans-Martin Fritsche; Thomas J Walton; Christopher G Wood; Karim Bensalah; Pierre I Karakiewicz; Francesco Montorsi; Vitaly Margulis; Shahrokh F Shariat Journal: J Urol Date: 2012-10-24 Impact factor: 7.450
Authors: B J Dicken; L D Saunders; G S Jhangri; C de Gara; C Cass; S Andrews; S M Hamilton Journal: Ann Surg Oncol Date: 2004-05-18 Impact factor: 5.344
Authors: Sang Hun Song; Chang Hee Ye; Sangchul Lee; Sung Kyu Hong; Seok-Soo Byun; Sang Eun Lee; Jong Jin Oh Journal: J Cancer Res Clin Oncol Date: 2019-09-09 Impact factor: 4.553
Authors: Melanie Biesinger; Nele Eicken; Alexander Varga; Michael Weber; Milos Brndiar; Georg Erd; Peter Errhalt; Klaus Hackner; Sarah Hintermair; Alexander Petter-Puchner; Axel Scheed; Elisabeth Stubenberger; Bahil Ghanim Journal: Cancers (Basel) Date: 2022-04-08 Impact factor: 6.575